Literature DB >> 8289395

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.

H E Farrell1, C S McLean, C Harley, S Efstathiou, S Inglis, A C Minson.   

Abstract

Several approaches to the production of vaccines to human herpesviruses have been proposed. Subunit vaccines, subunits delivered by live vectors, and rationally attenuated vaccines have all been shown to be efficacious in animal models but suffer from uncertainties as to the roles of individual genes involved in pathogenesis and the most relevant components of the immune response required for protection in humans and the target antigens involved. With these problems in mind, we examined the vaccine potential of a fully disabled herpes simplex virus type 1 mutant that is capable of only a single round of replication, since a virus of this type should induce the full spectrum of immune responses but has no pathogenic potential. A virus has been described which lacks essential glycoprotein H (gH) and can be propagated in a cell line which supplies gH in trans (A. Forrester, H. Farrell, G. Wilkinson, J. Kaye, N. Davis-Poynter, and T. Minson, J. Virol. 66:341-348, 1992). Infection of normal cells with this mutant is indistinguishable from a wild-type infection, except that the resulting progeny are gH negative and noninfectious: the virus is self-limiting. Infection of mice by the ear pinna route was similarly self-limiting in that input infectivity decreased rapidly at the inoculation site and no infectivity was detected in sensory ganglia. Animals given a wide range of doses of the gH-negative mutant produced both humoral and T-cell responses to herpes simplex virus type 1 and proved solidly resistant to challenge with a high dose of wild-type virus. The gH-negative mutant is presumably capable of establishing a latent infection, but since no infectious virus was detected in numerous attempts to reactivate the mutant, the risk of a pathogenic outcome is minimal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289395      PMCID: PMC236530          DOI: 10.1128/JVI.68.2.927-932.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  An analysis of the biological properties of monoclonal antibodies against glycoprotein D of herpes simplex virus and identification of amino acid substitutions that confer resistance to neutralization.

Authors:  A C Minson; T C Hodgman; P Digard; D C Hancock; S E Bell; E A Buckmaster
Journal:  J Gen Virol       Date:  1986-06       Impact factor: 3.891

2.  Protection against Marek's disease by vaccination with a herpesvirus of turkeys.

Authors:  W Okazaki; H G Purchase; B R Burmester
Journal:  Avian Dis       Date:  1970-05       Impact factor: 1.577

3.  Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.

Authors:  L R Stanberry; D I Bernstein; R L Burke; C Pachl; M G Myers
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

4.  Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis.

Authors:  P C Weber; M Levine; J C Glorioso
Journal:  Science       Date:  1987-05-01       Impact factor: 47.728

5.  Role of antibody in primary and recurrent herpes simplex virus infection.

Authors:  A Simmons; A A Nash
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

6.  Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation.

Authors:  H Openshaw; L V Asher; C Wohlenberg; T Sekizawa; A L Notkins
Journal:  J Gen Virol       Date:  1979-07       Impact factor: 3.891

7.  Pathogenesis of herpes simplex virus in B cell-suppressed mice: the relative roles of cell-mediated and humoral immunity.

Authors:  A K Kapoor; A A Nash; P Wildy
Journal:  J Gen Virol       Date:  1982-07       Impact factor: 3.891

8.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice.

Authors:  E McLaughlin-Taylor; D E Willey; E M Cantin; R Eberle; B Moss; H Openshaw
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

10.  Vaccines against Aujeszky's disease: evaluation of their efficacy under standardized laboratory conditions.

Authors:  P W de Leeuw; J T van Oirschot
Journal:  Vet Q       Date:  1985-07       Impact factor: 3.320

View more
  25 in total

Review 1.  Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Authors:  L R Stanberry
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

2.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

5.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1.

Authors:  Huali Jin; Yijie Ma; Zhipeng Yan; Bellur S Prabhakar; Bin He
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

7.  Pseudorabies virus glycoprotein L is necessary for virus infectivity but dispensable for virion localization of glycoprotein H.

Authors:  B G Klupp; W Fuchs; E Weiland; T C Mettenleiter
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 8.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

9.  Herpes Simplex Virus 1 Interaction with Myeloid Cells In Vivo.

Authors:  Maitreyi Shivkumar; Clara Lawler; Ricardo Milho; Philip G Stevenson
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.